Printer Friendly

Bill & Melinda Gates Foundation provides grant of USD267,870 to Southwest Research Institute.

M2 PHARMA-June 29, 2018-Bill & Melinda Gates Foundation provides grant of USD267,870 to Southwest Research Institute

(C)2018 M2 COMMUNICATIONS

The Bill & Melinda Gates Foundation has provided a grant of USD267,870 to the United States-based Southwest Research Institute (SwRI) to develop new technology to decrease the cost of artemisinin, the primary drug used to treat malaria, it was reported yesterday.

'Malaria is a huge problem affecting people worldwide,' said Dr Shawn Blumberg, a research scientist in SwRI's Chemistry and Chemical Engineering Division. 'Malaria remains one of the oldest known diseases to plague humans. We will be working to develop a new chemistry technique to develop artemisinin treatment.'

Presently, Artemisinin is extracted from the sweet wormwood plant, which takes around eight-months to mature and yields about 15 grams of artemisinin for every kilogram of plant. Previous efforts to lower the cost of artemisinin involved the use of bioengineered yeast to produce artemisinic acid, a synthetic precursor of the drug. This process, however, has yet to replace sweet wormwood as the primary source of the drug. Southwest Research Institute will develop a novel process to use the more abundant Amorpha-4, 11-diene as a cost-effective starting material to make high-quality, semisynthetic artemisinin. SwRI is collaborating with Dr Doug Frantz, who holds the Max and Minnie Tomerlin Voelcker Distinguished Professorship in Chemistry at The University of Texas at San Antonio, on this new technology. The grant was awarded in April 2018 and will run until April 2019.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 29, 2018
Words:255
Previous Article:Array BioPharma's Braftovi (encorafenib) capsule and Mektovi (binimetinib) tablet combination approved by US FDA.
Next Article:Episurf Medical ready to file IDE application to the US FDA for the Episealer knee implant.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters